A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Trial Profile

A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Mar 2018 Planned End Date changed from 23 Jul 2019 to 12 Mar 2020.
    • 13 Mar 2018 Planned primary completion date changed from 17 Sep 2018 to 24 Jul 2018.
    • 18 Sep 2017 Planned End Date changed from 1 Jul 2018 to 23 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top